Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio
Astrazeneca Plc (NY: AZN)
44.58 USD  -0.83 (-1.83%)
Official Closing Price  /  Updated: 6:30 PM EDT, Aug 23, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 3,759,900
Open 45.28
Bid (Size) 44.30 (4)
Ask (Size) 44.58 (1)
Prev. Close 45.41
Today's Range 44.50 - 45.67
52wk Range 35.30 - 45.69
Shares Outstanding 2,533,294,824
Dividend Yield 3.07%
Performance
YTD
+17.94%
+17.94%
1 Month
+2.46%
+2.46%
3 Month
+17.28%
+17.28%
6 Month
+7.42%
+7.42%
1 Year
+15.49%
+15.49%
Top News
More News
FARXIGA Met Primary Endpoint in Landmark Phase III DAPA-HF Trial for the Treatment of Patients With Heart Failure
AstraZeneca today announced positive results from the landmark Phase III DAPA-HF trial which showed that FARXIGA (dapagliflozin) met the primary composite endpoint with a statistically-significant and... Read More
from Business Wire News Releases
Bulls And Bears Of The Week: Chevron, Disney, Target And More
Benzinga has examined the prospects for many investor favorite stocks over the past week. Bullish calls included oil and tobacco ... Read More
category CVX , TGT , MO , and 8 more.
from Benzinga
More News
Read More
10 Biopharmaceutical Companies Trying To Cure Cancer
category cancer , General , NVS , and 17 more.
from Benzinga
CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia
from Business Wire News Releases
UPDATE 2-GSK builds oncology pipeline as drug shown to help myeloma patients
category companyNews
from Reuters: Company News
AstraZeneca's Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study
category Health Care , News , Market News , and 4 more.
from Benzinga
LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer
from Business Wire News Releases
UPDATE 2-AstraZeneca Imfinzi combination fails advanced lung cancer study
category companyNews
from Reuters: Company News
China adds 148 drugs to key insurance list - state media
category companyNews
from Reuters: Company News
UPDATE 1-European shares gain for third straight session, AstraZeneca boosts
category companyNews
from Reuters: Company News
Sainsbury continues climb from 30-year low as FTSE 100 edges higher
category UK:UKX , AZN , UK:AZN , and 11 more.
from MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.